EyePoint (EYPT) Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 136,700 shares of EyePoint common stock to seven new employees. The stock options were granted on May 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- Positive Buy Rating for EyePoint Pharmaceuticals Driven by Clinical Progress and Strong Financial Position
- EyePoint Pharma’s Promising Q1 2025 Financial Results
- EyePoint Pharma’s Earnings Call Highlights Positive Momentum
- EyePoint Pharmaceuticals: Strong Buy Rating Backed by Promising Clinical Trial Progress and Market Potential
- EyePoint Pharmaceuticals Reports Q1 2025 Financial Results